Medical imaging

Gallium Semiconductor Celebrates the Grand Opening of its Nijmegen R&D Center

Retrieved on: 
Wednesday, May 18, 2022 - 6:44pm

Gallium Semiconductor is pleased to announce the grand opening of its European R&D center in a ceremony at Kerkenbos 1224 in Nijmegen.

Key Points: 
  • Gallium Semiconductor is pleased to announce the grand opening of its European R&D center in a ceremony at Kerkenbos 1224 in Nijmegen.
  • Gallium Semi welcomed many of its valued customers, partners and vendors from the Europe region to dedicate the R&D center.
  • Nijmegen was an obvious choice for Gallium Semis new European R&D center, said Kin Tan, CEO of Gallium Semi.
  • The Nijmegen office is a fitting home for Gallium Semis European engineers designing and developing RF semiconductor solutions to support 5G and beyond networks.

Insights on the Wearable Sensor Global Market to 2028 - Burgeoning Popularity of Connected Devices Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022 - 3:45pm

The "Wearable Sensor Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Sensor Type, Application and Vertical" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Wearable Sensor Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Sensor Type, Application and Vertical" report has been added to ResearchAndMarkets.com's offering.
  • With the growing consumer awareness, the adoption of smart wearable devices is on the rise in the healthcare sector.
  • Fit bits, smartwatches, and pulse oximeters are among the wearable systems incorporated with optical sensors to provide real-time patient health tracking solutions.
  • Thus, the increasing demand for wearables devices in healthcare applications drives the global wearable sensors market.

Global Bispecific Antibody Market Report to 2028 - Featuring Genentech, Genmab and Merus Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022 - 3:12pm

Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028" Report Highlights:

Key Points: 
  • Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028" Report Highlights:
    Global Bispecific Antibody Market Opportunity: > US$ 20 Billion
    Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021)
    Approved Bispecific Antibodies In Market: 4 Antibodies
    Ongoing Clinical Trials Assessment by Status, Phase, and Region
    The unique achievements gathered through the monoclonal antibody market led to the identification of a novel wave of antibody market classified as the Bispecific cancer antibody market.
  • In a very imperative and innovative way, bispecific cancer antibody market applications have prompted oncology researchers to multiply the healthcare benefits received by the patients suffering from different types of cancers.
  • The whole procedure followed by the drugs available on the market involves targeting two specific molecules present on the surface of cancer antigens.
  • Currently 3 Bispecific Antibodies Blincyto, Hemlibra & Rybrevant Are Commercially Available In Market, Hemlibra Accounts For More Than 80% Of Global Bispecific Antibody Market
    In the past few years, global bispecific cancer antibody market has cleared its clinical evaluation for different types of cancers which involves: cancer at early stage, last stage and solid cancers.

Prosperdtx Launches Strategic Collaboration With Health Equity Researchers and Seqster to Improve Health Equity for Cancer Patients

Retrieved on: 
Wednesday, May 18, 2022 - 3:14pm

Our collaboration with Seqster will enable us to demonstrate how Prosperdtxs digital health platform can help cancer patients live better lives with improved and cost-effective health outcomes.

Key Points: 
  • Our collaboration with Seqster will enable us to demonstrate how Prosperdtxs digital health platform can help cancer patients live better lives with improved and cost-effective health outcomes.
  • Seqsters Operating System will enable Prosperdtx to deliver precision cancer care to cancer patients in real-time, said Joseph Swiader, co-founder and CEO of Prosperdtx.
  • Prosperdtx is maximizing the continuity of cancer care so that patients can live longer, better lives while reducing the cost of healthcare.
  • Seqster has nationwide coverage of EHRs from hospitals and medical groups, genomic DNA, wearables, pharmacy, and social determinants of health data.

C2N Diagnostics Introduces P-tau Multi-Analyte Assay for Research Use Only to Advance Alzheimer’s Disease and Brain Health Field

Retrieved on: 
Wednesday, May 18, 2022 - 3:06pm

C2N believes this RUO development broadens the panel of cutting-edge biomarkers that will ultimately aid in disease diagnosis and brain health evaluations.

Key Points: 
  • C2N believes this RUO development broadens the panel of cutting-edge biomarkers that will ultimately aid in disease diagnosis and brain health evaluations.
  • Under C2Ns p-tau MAA RUO, researchers can evaluate and characterize its ability to precisely identify Alzheimers pathology at early stages of disease.
  • GHR is committed to our deep partnership with C2N as we together reimagine whats possible in the prevention and treatment of Alzheimers disease.
  • C2N strives to provide exceptional laboratory services and products in the field of brain health.

Worldwide Digital Biomarkers Industry to 2028 - Early Detection of Neurological Disorders Using Digital Biomarkers Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022 - 1:21pm

The global digital biomarkers market report highlights that the market was valued at $1,808.3 million in 2021 and is expected to reach $16,174.0 million by 2028.

Key Points: 
  • The global digital biomarkers market report highlights that the market was valued at $1,808.3 million in 2021 and is expected to reach $16,174.0 million by 2028.
  • As a result, disease diagnosis will become more prevalent, and the global market for digital biomarkers will expand.
  • What technological developments are projected to have the maximum influence on the global digital biomarkers market?
  • What are the key strategies being adopted by market players in the global digital biomarkers market?

Cohesity Expands Marketplace With Integrations, Empowering Organizations to Better Manage Their Data and Protect It From Cyber Attacks

Retrieved on: 
Wednesday, May 18, 2022 - 2:00pm

These solutions can help customers advance security, extend the value of the Cohesity next-gen data management platform, and address data management challenges.

Key Points: 
  • These solutions can help customers advance security, extend the value of the Cohesity next-gen data management platform, and address data management challenges.
  • As the volume and value of data skyrockets for organizations of all shapes and sizes, the vulnerability of this data increases as well.
  • Parablu Endpoint backup for laptops and mobile devices stores backup files on Cohesity, allowing organizations to restore endpoint data from Cohesity backups.
  • We make it easy to protect, manage, and derive value from data across the data center, edge, and cloud.

Global Next-Generation Sequencing Market Report to 2027 - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022 - 11:43am

It includes procedures such as sequencing by synthesis (SBS), ion semiconductor sequencing, nanopore sequencing and single-molecule real-time (SMRT) sequencing.

Key Points: 
  • It includes procedures such as sequencing by synthesis (SBS), ion semiconductor sequencing, nanopore sequencing and single-molecule real-time (SMRT) sequencing.
  • What is the breakup of the global next-generation sequencing (NGS) market based on the sequencing type?
  • What are the key regions in the global next-generation sequencing (NGS) market?
  • 10. Who are the key players/companies in the global next-generation sequencing (NGS) market?

Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use

Retrieved on: 
Wednesday, May 18, 2022 - 2:00pm

Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company is undertaking manufacturing and development of PRP for human use.

Key Points: 
  • Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company is undertaking manufacturing and development of PRP for human use.
  • PRP is the Companys lead product candidate and is a novel pharmaceutical formulation consisting of two proenzymes to be administered by I.V.
  • A proprietary purification process has been developed by Propanc and successful scale up of the bulk drug substances has been completed.
  • Over the last decade, Propanc has undertaken the manufacturing and development of proenzymes as an I.V.

Wave Neuroscience, Tomahawk Charitable Solutions and Special Operations Care-Fund Announce Continuation of Partnership to Support Military Service Members

Retrieved on: 
Wednesday, May 18, 2022 - 2:03pm

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220518005404/en/
    The leader in personalized braincare, Wave Neuroscience delivers innovative technologies for Special Operations Forces members to restore neurological wellness.
  • Our Special Operations Forces commit their lives to protecting our country and it has been an honor to partner with SOC-F to care for these service members.
  • This organization exists to support our Special Operations Forces members and providing access to Wave Neuroscience technologies has been life-changing for them and their families.
  • We are excited to continue the partnership with SOC-F and Wave Neuroscience, said Keith Walawender, CEO of Tomahawk Strategic Solutions.